Drugs made to address prostate cancer might treat COVID-19 patients
Category: #headline  By Mateen Dalal  Date: 2020-11-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Drugs made to address prostate cancer might treat COVID-19 patients

Two drugs currently under development for the treatment of aggressive prostate cancer would reportedly be tested to fight the deadliest response against COVID-19 infection, ARDS (acute respiratory distress syndrome).

An Advance Queensland Fellowship of approximately $150,000 has been awarded to Dr. Lisa Philp to test the drugs which she and Prof. Colleen Nelson, from QUT Faculty of Health School of Biomedical Science, are making to treat advanced prostate cancer which might also treat and or prevent ARDS (acute respiratory distress syndrome).

Dr. Philp and Prof. Nelson, along with their research team, based out of the Translational Research Institute, discovered that their research on two hormones, which are secreted by body fat, that regulate the growth of prostate cancer tumor in the body, might also be beneficial in driving the severe, rapid-onset lung inflammation which causes the death of critical COVID-19 patients.

Dr. Philp stated that the team had been working with two USA-based biotech companies to further their research on the novel drugs for Phase 1 clinical trial within prostate cancer patients.

Professor Nelson, who is also the Director of the Australian Prostate Cancer Research Centre, Queensland, stated that the research team had been working on two new drugs that effectively target two fat hormones. One hormone that has anti-inflammatory effect, and another that is pro-inflammatory, each involved in prostate cancer progression.

Nelson further added that through the center’s knowledge and data of coronavirus research, the team came to the hypothesis that these drugs might be effective for ARDS treatment. Subsequently, the center rapidly put together new collaborations with ICU clinician-scientists at Royal Brisbane and Women’s Hospital, and Princess Alexandra Hospital, and brought its existing industry partners in the new research area to test the hypotheses and move the research towards proof of principle in order to translate it into COVID-19 treatment as soon as possible.

Source credit: https://www.qut.edu.au/news?id=171029

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

AstraZeneca’s COVID-19 vaccine manufacturing error clouds trial data
AstraZeneca’s COVID-19 vaccine manufacturing error clouds trial data
By Mateen Dalal

AstraZeneca and Oxford University have recently encountered a manufacturing error of their experimen...

Singapore Airlines raises $500M with the help of 10-year bonds
Singapore Airlines raises $500M with the help of 10-year bonds
By Mateen Dalal

SIA (Singapore Airlines), a flag carrier airline of the country of Singapore, has reportedly raised ...

New TMG 360 Media to optimize time to market for Healthtech companies
New TMG 360 Media to optimize time to market for Healthtech companies
By Mateen Dalal

TMG 360 Media, a novel digital platform created for driving brand awareness, strategic partnerships,...